Hogyan értelmezzük a PCT eredményeket a betegágynál?
Molnár Zsolt
zsoltmolna@gmail.com
Aneszteziológiai és Intenzív Terápiás Intézet
Szegedi Tudományegyetem
Hogyan rtelmezzk a PCT eredmnyeket a beteggynl? Molnr Zsolt - - PowerPoint PPT Presentation
Hogyan rtelmezzk a PCT eredmnyeket a beteggynl? Molnr Zsolt zsoltmolna@gmail.com Aneszteziolgiai s Intenzv Terpis Intzet Szegedi Tudomnyegyetem Mi az a szepszis? A szepszis nem definitv betegsg
zsoltmolna@gmail.com
Aneszteziológiai és Intenzív Terápiás Intézet
Szegedi Tudományegyetem
immature forms)
immature forms)
ACCP/SCCM. Crit Care Med 1992; 20: 864
I n s u l t
Endotoxin, Trauma, Sterile inflammation, Operation, etc.
Humoral activity
Interferon, Complement
M a c r o p h a g e s
TNF; IL-1,6,10; PAF
P M N
FR, PAF, Chemotaxis
E n d o t h e l
NO, E-selectin, NFkB
Fever, Metabolic changes
Sepsis, SIRS MSOF
Molnár and Shearer Br J Int Care Med 1998; 8: 12
„DAMP → → → → SIRS” versus „PAMP → → → → SIRS”
Surgery, Trauma, Pancreatitis Isch-reperf.
DAMP = Damage Assosiated Molecular Pattern PAMP = Pathogen Associated Molecular Pattern
G+ G- F
Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock
Medical patients: SIRS: PCT = 0.3 (0.1-1.0) ng/ml Septic shock: PCT = 8.4 (3.6-76.0) ng/ml Surgical patients: SIRS: PCT = 5.7 (2.6-8.4) ng/ml Septic shock: PCT = 34 (7-76) ng/ml
9.7 ng/ml, sens: 91% - spec: 74%
1 ng/ml, sens: 80% - spec: 94%
Clec’h et al. Crit Care Med 2006; 34:102-107
DAMP+PAMP PAMP
Pro- inlflammation Anti- inlflammation
Nature Reviews | Immunology Volume 13 | December 2013 | 862-874
Nature Reviews | Immunology Volume 13 | December 2013 | 862-874
Pro- inlflammation Anti- inlflammation
Study Design / data collection [n] Hospital Mortality ICU stay (d) Hospital stay (d) Kaukonen et al. (2014) Australien / Neuseeland, 2011 Retrospektive, incidence, administrative data 12,213 19,8 % 3,2 (1,6-6,9) 13,5 (7,0-25,9) Levy et al. (2012) USA, 2005-2010 Prospektive, registry, not representative 18,766 28,3% 4,2 (2,2-8,9) 10,5 (5,8-18,9) Europe 2005-2010 6,609 41,1% 7,8 (3,4-17,2) 22,8 (11,1-43,3) Heublein et al. (2013) Deutschland, 2011 Retrospektive, incidence study, administrative data 89,907 46,5%
Deutschland, 2003 Prospektive, one-day prevalence, representative 415 55,2% 12,3 (6-16) 24 (13-38) Jena Sepsisregistry Deutschland (Jena), 2011 Prospektive, monocentric, incidence study, registry 388 46,9% 10 (4-23) 27 (16-43,2) Brunkhorst FM et al. IntensivNews 2014
– 10 positive – 7 negative – 55 no difference
(Crit Care Med 2008; 36:1311–1322)
Galicier L and Richet H. Infect Control Hosp Epidemol 1985; 6: 487
Christ-Crain M, et al. Lancet 2004; 363: 600-7
Trásy D et al.,(under submission)
Increasing procalcitonin may be a good indicator of starting empirical antibiotic treatment in critically ill patients
Patients with suspected infection = 209
Infection = 85 PCT available at T-1 = 114 No-infection = 29
Trásy D et al.,(Manuscript under review)
Trásy D et al.,(Manuscript under review)
85 % 77 % Increasing PCT/24 h: May be a good indicator of infection No change in PCT/24 h: May be a good indicator of no infection
Medical patients: SIRS: PCT = 0.3 (0.1-1.0) ng/ml Septic shock: PCT = 8.4 (3.6-76.0) ng/ml Surgical patients: SIRS: PCT = 5.7 (2.6-8.4) ng/ml Septic shock: PCT = 34 (7-76) ng/ml
9.7 ng/ml , sens: 91% - spec: 74% 1 ng/ml , sens: 80% - spec: 94% Clec’h et al. Crit Care Med 2006; 34:102-107
BMC Infectious Diseases 2007, 7:21
Trásy D et al.,(In review)
Proven infection = 169 Effective AB = 127 (77%) Ineffective AB = 38 (23%) No infection = 44 Patients with suspected infection= 209
Trásy D et al.,(In review)
Lancet 2010; 375: 463-74
Bouadma L, et al. Lancet 2010; 375: 463-74
Fazakas J, Trásy D, Molnar Z. Annual Update in Intensive and Emergency Medicine 2016
Fazakas J, Trásy D, Molnar Z. Annual Update in Intensive and Emergency Medicine 2016
Journal of Immunology Research, 2015; in press
Auguste Rodin, 1880
Hamvas Béla 1897-1968
A Noszty fiú este a Tóth Marival
1813-1871
A falu jegyzője
1847-1910
Rokonok
1879-1947